AstraZeneca PLC (AZN), along with pharmaceutical company Daiichi Sankyo, Monday announced that fam-trastuzumab deruxtecan-nxki, sold under the brand name ENHERTU, has been granted the Food and Drug Administration's Breakthrough Therapy Designation in the U.S. for adult patients.
The drug is used to treat HER2-positive early breast cancer with residual invasive disease in the breast and/or axillary lymph nodes after neoadjuvant treatment and high risk of disease recurrence.
The designation is supported by data from the DESTINY-Breast05 Phase III trial, which demonstrated that ENHERTU may help halt invasive disease recurrence over the current standard of care.
In the pre-market hours, AZN is trading at $91.38, up 0.07 percent on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Health News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.